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Effect of thalidomide on tumour necrosis factor production and
anti-tumour activity induced by 5,6-dimethylxanthenone-4-acetic acid
L-M Ching, Z-F Xu, BH Gummer, BD Palmer, WR Joseph and BC Baguley
Cancer Research Laboratory, University ofAuckland School ofMedicine, Auckland 1000, New Zealand.
Summary The investigational anti-tumour agent, 5,6-dimethylxanthenone-4-acetic acid (5,6-MeXAA), an
analogue of flavone acetic acid (FAA), has been scheduled for clinical evaluation. Like FAA, 5,6-MeXAA
exhibits excellent experimental anti-tumour activity and is an efficient inducer of cytokines in mice. We have
examined the effect of pharmacological suppression of tumour necrosis factor (TNF) production on the
anti-tumour activity of 5,6-MeXAA, taking advantage of previous observations that TNF production in
response to endotoxin in vitro is inhibited by thalidomide. Thalidomide at doses of between 8 and 250 mg kg-'
efficiently suppressed serum TNF activity in response to 5,6-MeXAA at its optimal TNF inducing dose of
55 mg kg-'. Suppression was achieved when thalidomide was administered at the same time as, or up to 4 h
before, 5,6-MeXAA. Under conditions in which TNF activity was suppressed, the degree of tumour haemorr-
hagic necrosis and the proportion of cures in the subcutaneous Colon 38 tumour were increased. In mice
administered thalidomide (100 mg kg-') together with 5,6-MeXAA (30mgkg-1), complete tumour regression
was obtained in 100% of mice, as compared with 67% in mice receiving 5,6-MeXAA alone. The results
suggest a possible new application for thalidomide and pose new questions about the action of 5,6-MeXAA
and related compounds.
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The investigational anti-tumour agent, 5,6-dimethylxanthe-
none-4-acetic acid (5,6-MeXAA; see Figure 1 for structure),
has been scheduled for clinical evaluation as a more potent
analogue of the biological response modifier flavone acetic
acid (FAA). Both 5,6-MeXAA and FAA exhibit excellent
anti-tumour activity and are efficient inducers of cytokines in
mice (Mace et al., 1990; Ching et al., 1994a; Philpott et al.,
1995). Antibodies to tumour necrosis factor (TNF) inhibit
FAA-induced tumour vascular collapse (Mahadevan et al.,
1990), a critical early effect of the drug leading to tumour
ischaemia and necrosis (Bibby et al., 1989; Zwi et al., 1989).
Treatment with antibodies to TNF also leads to a reduction
in toxicity and in the anti-tumour action of FAA (Pratesi et
al., 1990). We have shown that within 2 h of administration
serum TNF activity is elevated following treatment with
5,6-MeXAA or FAA but not with an inactive analogue,
8-methylxanthenone-4-acetic acid (8-MeXAA) (Philpott et
al., 1995). These studies suggest an important role for TNF
in the anti-tumour effects of FAA. However, in contrast to
these results, lipopolysaccharide (LPS) does not induce cures
or significant tumour growth delays in mice with implanted
Colon 38 tumours despite inducing serum TNF to higher
levels than does 5,6-MeXAA at its optimal anti-tumour dose
(Ching et al., 1994a). Thus, the elevation of serum TNF is
not solely responsible for the anti-tumour effects of 5,6-
MeXAA, and other cytokines or immune functions must
contribute to the cures and growth delays observed with this
agent.
In this report, we have examined the effect of pharma-
cological suppression of TNF production on the anti-tumour
activity of 5,6-MeXAA. We have taken advantage of the
observation that thalidomide (structure in Figure 1) inhibits
TNF production by human peripheral blood monocytes
induced by LPS in vitro (Sampaio et al., 1991). In contrast to
other inhibitors such as dexamethasone, which suppress pro-
duction of a spectrum of cytokines, thalidomide suppresses
TNF production by selectively increasing the rate ofdegrada-
tion of TNF mRNA without affecting interleukin 1 (IL-1),
granulocyte-macrophage colony-stimulating factor (GM-
CSF) or IL-6 production (Moreira et al., 1993). The results
provide new insights into the mode of action of 5,6-MeXAA.
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Materials and methods
Materials
5,6-MeXAA and 8-MeXAA were synthesised in this labora-
tory (Rewcastle et al., 1989, 1991), were freshly dissolved in
5% (v/w) sodium bicarbonate for each experiment and were
protected from light (Rewcastle et al., 1990). (- )-Thalido-
mide was also synthesised in this laboratory by a previously
reported method (Casini and Ferappi, 1964) and freshly dis-
solved for each experiment in dimethyl sulphoxide (DMSO).
Mice and tumours
All experiments were carried out using 8- to 12-week-old
(C57BL/6 x DBA/2)Fj (BDF,) mice bred in the animal
facility. Fragments of Colon 38 tumour (1 mm3) were im-
planted subcutaneously in the flank of anaesthetised (sodium
pentobarbital, 90 mg kg-') animals.
Serum preparation and TNFbioassay
Blood was collected from mice anaesthetised with halothane,
coagulated overnight at 4°C and centrifuged for 30min at
2000 g. The serum layer was removed and stored at - 20°C
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Figure 1 Chemical structures of 5,6-MeXAA and thalidomide.Effect of thalidomide on 5,6-MeXAA anti-tumour activity
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until assay for TNF. TNF activity was measured using the
standard L929 cytotoxicity assay as previously described
(Hogan and Vogel, 1990). Briefly, L929 cells (3 x 104 per
well) were allowed to adhere overnight to the bottom of
flat-bottomed microwells. Actinomycin D (final concentration
8 tLg ml-') was then added to the wells followed by serial
dilutions of the serum to be assayed. Cell killing was assessed
after 24 h by a colorimetric assay using 3-(4,5-dimethyl-2-
thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide (MTT) as
previously described (Finlay et al., 1986). One unit of TNF
was defined as that required to kill 50% of the L929 cells.
Assessment ofhaemorrhagic necrosis
Tumour-bearing mice were injected intraperitoneally with
drug. 5,6-MeXAA was administered in a volume of 0.01 ml
per g body weight and thalidomide in a volume of 2.5 "tl per
g body weight. The tumours were removed 24 h later, fixed in
formalin (10%) and embedded in paraffin wax. Sections were
stained with haematoxylin and eosin, examined on a grid
marked at 0.4 mm intervals and scored for percentage nec-
rosis as previously described (Baguley et al., 1989). Haemorr-
hagic necrosis assays were carried out using tumours between
6 and 10mm across in their widest diameter.
Growth delay determinations
Experiments were carried out when tumours had reached
approximately 5 mm in diameter, generally 10-14 days after
implantation. Mice bearing Colon 38 tumours were treated
with drug and the tumours measured three times thereafter
weekly using callipers. Tumour volumes were calculated as
0.52aib, where a and b are the minor and major axes of the
tumour. The arithmetic means and standard error of the
means were calculated for each time point, counting cured
animals as having zero tumour volume, and expressed as
fractions of the pretreatment tumour volume. Growth delay
was determined as the difference in the number of days
required for the control and treated tumours to reach four
times the pretreatment volume.
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Results
Effect ofthalidomide on serum TNFactivity induced by
5,6-MeXAA
Sera from individual (non-tumour-bearing) mice, treated 2 h
previously with 5,6-MeXAA (55 mg kg-') either alone or
together with thalidomide (100 mg kg-'), were assayed for
TNF (Figure 2). The dose of 5,6-MeXAA was chosen
because it induced the maximal TNF response, and although
it was above the maximum tolerated dose in long-term
experiments it caused no toxicity over the time of the assay
(Philpott et al., 1995). The (geometric) mean TNF activities
in serum were 1960 units ml-' for mice given 5,6-MeXAA
alone, 160 units ml-' for mice given 5,6-MeXAA plus
thalidomide, 13 units ml-' in untreated control mice and 11
units ml-' in mice administered thalidomide only. Despite
some scatter in the group receiving 5,6-MeXAA plus
thalidomide, all of the determinations lay below the mean of
the group which received 5,6-MeXAA only and a statistically
significant suppression of 83% (P<0.001) was obtained.
Subsequent experiments were carried out using TNF deter-
minations from serum pooled from three mice per group.
Inhibition of the response to 5,6-MeXAA was obtained fol-
lowing doses of thalidomide ranging from 8 to 250 mg kg-1
(Figure 3). Inhibition was observed when thalidomide was
given either at the same time as or up to 4 h before 5,6-
MeXAA (Figure 4). No suppression was obtained in mice
pretreated with thalidomide 12 or 24 h before 5,6-MeXAA.
Thalidomide on its own, or dimethyl sulphoxide (DMSO) in
which it was dissolved, had no toxic effect on the mice or
TNF activity (Figures 3 and 4). The time course in the
presence and absence of thalidomide, as shown in Figure 5,
indicates that thalidomide suppressed rather than delayed
TNF production.
Effect ofthalidomide in tumour-bearing mice
Mice bearing Colon 38 tumours were given 5,6-MeXAA
(30 mg kg-'), which was the maximum tolerated dose in
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Figure 2 Suppression of 5,6-MeXAA-induced serum TNF act-
ivity by thalidomide. Sera from individual mice treated 2 h before
with 5,6-MeXAA (55 mg kg-') alone or together with thalido-
mide (100 mg kg-'), or with thalidomide alone and control mice
were assayed for TNF activity. Each point represents a deter-
mination from an individual mouse. Squares mark the group
geometric mean values.
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Figure 3 Suppression of serum TNF by thalidomide at different
doses. Mice were injected with 5,6-MeXAA (55 mg kg-') and
thalidomide (dose in mg kg-' shown in brackets), and after 2 h
sera were collected, pooled (three mice per group) and assayed
for TNF activity.
If
in nnn - VVVV -long-term experiments as well as the optimal anti-tumour
dose. Some mice were also given thalidomide (100mgkg-').
Three mice per group were tested for serum TNF activity
after 2 h and the other five mice in each group were sacrificed
after 24 h for assessment of tumour haemorrhagic necrosis.
TNF activity induced by 5,6-MeXAA in tumour-bearing
mice was similar to that obtained from age- and sex-matched
non-tumour-bearing control mice, and was similarly inhibited
by thalidomide (results not shown). However, suppression of
5,6-MeXAA-induced haemorrhagic necrosis was not observ-
ed following the same thalidomide treatment (Figure 6).
Rather, the tumours from mice which had received both
5,6-MeXAA and thalidomide showed greater amounts of
haemorrhagic necrosis than tumours treated with 5,6-
MeXAA alone.
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The growth delays of Colon 38 tumours growing in mice
treated with 5,6-MeXAA (30 mg kg-1) with or without
thalidomide (100 mg kg-') are shown in Figure 7. Two
independent experiments were performed, and since the data
were comparable they were combined. Mice treated with
5,6-MeXAA alone provided a mean tumour growth delay of
20 days and complete cures in 8/12 mice. Thalidomide alone
provided a small growth delay and no cures. However, when
thalidomide was administered together with 5,6-MeXAA, the
anti-tumour response was greater than that of mice treated
with 5,6-MeXAA alone (Figure 7) with 8/8 cures. Thus,
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Figure 4 Effects of thalidomide administered at different times
before 5,6-MeXAA. Mice were treated with thalidomide (100 mg
kg-') and at different times later with 5,6-MeXAA (55 mg kg-').
After a further 2 h sera were collected, pooled (three mice per
group), and assayed for TNF activity. Combined results from
two experiments. Solvent controls were injected with dimethyl
sulphoxide.
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Figure 6 Effect of thalidomide on 5,6-MeXAA-induced haemor-
rhagic necrosis. Mice bearing Colon 38 tumours were treated
with 5,6-MeXAA (30mg kg-') with or without thalidomide (50
or 100 mg kg-') as indicated, and after 24 h the tumours were
removed and assessed for haemorrhagic necrosis.
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Figure 5 Time course of TNF production in response to 5,6-
MeXAA (55 mg kg-') in the presence (shaded bars) and absence
(open bars) of thalidomide (100mgkg-').
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Figure 7 Effect of thalidomide on 5,6-MeXAA-induced tumour
growth inhibition. Colon 38 tumours were measured either un-
treated (0) or following treatment with 5,6-MeXAA (30mg
kg-') (A), 5,6-MeXAA (30mgkg-') plus thalidomide (100mg
kg-') (@) or thalidomide (lOmgkg-') (0).
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although thalidomide effectively inhibited 5,6-MeXAA-in-
duced TNF activity in the serum of tumour-bearing mice,
tumour haemorrhagic necrosis and cure rates were both
enhanced.
Discussion
Thalidomide is an effective inhibitor of LPS-induced TNF
production (Sampaio et al., 1991), and we have shown here
that thalidomide also inhibits TNF production in response to
5,6-MeXAA (Figures 2-5). Thalidomide also enhances anti-
tumour activity when administered in combination with 5,6-
MeXAA (Figures 6 and 7). This result was unexpected in
view of other studies demonstrating that administration of
antibodies to TNF inhibits tumour vascular collapse (Maha-
devan et al., 1990) and anti-tumour effects (Pratesi et al.,
1990) induced by FAA, an analogue of 5,6-MeXAA. Our
results using thalidomide show that under conditions where
systemic TNF activity has been suppressed, a vigorous
antitumour response is still obtained, and could simplistically
be interpreted as indicating that the anti-tumour effects
induced by 5,6-MeXAA are not dependent on systemic TNF
activity.
The source of the serum TNF is not clear. We have
previously demonstrated up-regulation of TNF mRNA in
mouse splenocytes treated with 5,6-MeXAA (Ching et al.,
1994b), but its contribution to TNF activity in the serum has
not been established. The serum TNF might also be pro-
duced by blood monocytes or by the liver. It is also not
known whether serum TNF levels reflect TNF activity within
the tumour. Localised TNF production by tumour-associated
macrophages may be more important than serum levels for
the anti-tumour activity of 5,6-MeXAA, and may continue
under conditions in which serum TNF production has been
reduced. Studies on the effects of thalidomide on 5,6-
MeXAA-induced TNF production in tumours are in pro-
gress.
Since thalidomide by itself has only a small effect on
haemorrhagic necrosis (Figure 6) and tumour growth (Figure
7), its ability to enhance the anti-tumour response of 5,6-
MeXAA was unexpected. TNF is angiogenic (Folkman and
Shing, 1992), and endogenously produced TNF may be con-
tributing to tumour growth by promoting tumour angio-
genesis. Inhibition of TNF production by thalidomide might
therefore lead to disruption of tumour angiogenesis. How-
ever, it is difficult to understand how a single dose of
thalidomide could lead to long-term effects and cures. One
possible explanation for the enhancement by thalidomide of
the 5,6-MeXAA anti-tumour effect might be that it prevents
the cleavage and release of TNF from the macrophages but
not its production within the cell. Thus, while circulating
TNF is decreased, a greater number of 'armed' macrophages
expressing cell-surface TNF are able to act against tumour
cells. The processing and cleavage of the TNF precursor to
the mature TNF involves several matrix metalloproteinase-
like enzymes, and metalloproteinase inhibitors have been
shown to block TNF secretion (Gearing et al., 1994;
McGeehan et al., 1994). The precise mechanism by which
thalidomide blocks TNF production is not known, although
it has been suggested that it is at the post-transcriptional
stage, perhaps by acceleration of TNF mRNA degradation
(Moreira et al., 1993). It would be of interest to determine
whether metalloproteinase inhibitors resemble thalidomide
when administered in conjunction with 5,6-MeXAA.
Thalidomide was withdrawn from the market as a sedative
agent in the 1960s because of its teratogenicity (Fabro et al.,
1967). However it is re-emerging as adjunct therapy for a
variety of diseases, including AIDS, leprosy, graft vs host,
cachexia associated with cancer, and other diseases which
show an involvement of TNF (Ehninger et al., 1993; McCor-
mick et al., 1994; Silva et al., 1994). TNF is produced in mice
in response to 5,6-MeXAA (Philpott et al., 1995), and the
haematological effects of the compound are more similar to
those induced by TNF than to those induced by conventional
anti-cancer agents (Ching et al., 1991). The demonstration
here that thalidomide suppresses systemic TNF activity and
concomitantly enhances anti-tumour activity induced by 5,6-
MeXAA suggests a possible new application for thalidomide.
5,6-MeXAA is scheduled for clinical evaluation in human
malignancies and an understanding of the action of thalido-
mide will be important in developing strategies to opt-imise
the anti-tumour response to this drug.
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